This study is a single-arm, observational, real-world study. The purpose of this study is to collect efficacy and safety data over a 5-year period following treatment of adult patients with r/r B-NHL with Ranicabtagene Autoleucel Injection. This study is expected to enroll no fewer than 200 patients.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed as relapsed/refractory B cell Non-Hodgkin Lymphoma through cytological or pathological tissue examination according to the WHO 2016 standards
Age ≥18 years old
Have already received treatment with Ranicabtagene Autoleucel Injection through commercial channels at a study center in China that has obtained the commercial certification by HRAIN Biotechnology Co., Ltd.
Voluntarily participate in this study and sign the informed consent form. For patients who do not have full capacity for civil conduct, informed consent must also be obtained from their legal guardians
You may not be if
Patients who previously received CAR-T cell therapy targeting CD19
Clareo Health | Non-Interventional Study of Ranicabtagene Autoleucel Injection for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
